Effectiveness and Cost-effectiveness of Immediate Versus Delayed Treatment of Hepatitis C Virus-Infected Patients in a Country With Limited Resources: The Case of Egypt

被引:28
|
作者
Obach, Dorothee [1 ,2 ,3 ]
Deuffic-Burban, Sylvie [1 ,2 ,3 ,4 ]
Esmat, Gamal [5 ]
Anwar, Wagida A. [6 ]
Dewedar, Sahar [6 ]
Canva, Valerie [7 ]
Cousien, Anthony [1 ,2 ,3 ]
Doss, Wahid [8 ]
Mostafa, Aya [6 ]
Pol, Stanislas [9 ,10 ]
Buti, Maria [11 ,12 ]
Siebert, Uwe [13 ,14 ]
Fontanet, Arnaud [15 ,16 ]
Mohamed, Mostafa K. [6 ]
Yazdanpanah, Yazdan [1 ,2 ,17 ]
机构
[1] INSERM, IAME, UMR 1137, F-75018 Paris, France
[2] Univ Paris Diderot, Sorbonne Paris Cite, F-75018 Paris, France
[3] Univ Lille Nord France, EA2694, Lille, France
[4] Univ Lille Nord France, INSERM, U995, Lille, France
[5] Cairo Univ, Fac Med, Dept Trop Med, Cairo, Egypt
[6] Ain Shams Univ, Fac Med, Dept Community Environm & Occupat Med, Cairo, Egypt
[7] CHRU Lille, Hop Huriez, Serv Malad Appareil Digestif & Nutr, Lille, France
[8] Natl Hepatol & Trop Med Res Inst, Cairo, Egypt
[9] Univ Paris 05, Unite Hepatol, Grp Hosp Cochin Hotel Dieu, Paris, France
[10] INSERM, U1016, Paris, France
[11] Hosp Gen Univ Valle Hebron, Dept Internal Med, Liver Unit, Barcelona, Spain
[12] Inst Carlos III, Ciber Ehd, Barcelona, Spain
[13] Univ Hlth Sci, UMIT, Hall In Tirol, Austria
[14] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA
[15] Hop Bichat Claude Bernard, Inst Pasteur, Emerging Dis Epidemiol Unit, F-75877 Paris 18, France
[16] Hop Bichat Claude Bernard, Chaire Dev & Sante, Conservatoire Natl Arts & Metiers, F-75877 Paris 18, France
[17] Hop Bichat Claude Bernard, Serv Malad Infect & Trop, F-75877 Paris 18, France
关键词
HCV; cost-effectiveness; resource-limited countries; Egypt; antiviral treatment; SUSTAINED VIROLOGICAL RESPONSE; QUALITY-OF-LIFE; VIRAL RESPONSE; FIBROSIS; PROGRESSION; MORBIDITY; RIBAVIRIN; CIRRHOSIS; GENOTYPE;
D O I
10.1093/cid/ciu066
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Because of logistical and economic issues, in Egypt, as in other resource-limited settings, decision makers should determine for which patients hepatitis C virus (HCV) treatment should be prioritized. We assessed the effectiveness and cost-effectiveness of different treatment initiation strategies. Methods. Using a Markov model, we simulated HCV disease in chronically infected patients in Egypt, to compare lifetime costs, quality-adjusted life expectancy (QALE), and the incremental cost-effectiveness ratio (ICER) of different treatment initiation strategies. Results. Immediate treatment of patients at stages F1/F2/F3 was less expensive and more effective than delaying treatment until more severe stages or not providing treatment (in patients diagnosed at F1: QALE = 18.32 years if treatment at F1 vs 18.22 if treatment at F2). Treatment of F4 patients was more effective than no treatment at all (QALE = 10.33 years vs 8.77 years) and was cost-effective (ICER = $1915/quality-adjusted life-year [ QALY]). When considering that affordable triple therapies, including new direct-acting antivirals, will be available starting in 2016, delaying treatment until stage F2, then treating all patients regardless of their disease stage after 2016, was found to be cost-effective (ICER = $33/QALY). Conclusions. In Egypt, immediate treatment of patients with fibrosis stage F1-F3 who present to care is less expensive and more effective than delaying treatment. However, immediate treatment at stage F1 is only slightly more effective than waiting for disease to progress to stage F2 before starting treatment and is sensitive to the forthcoming availability of new treatments. Treating patients at stage F4 is highly effective and cost-effective. In Egypt, decision makers should prioritize treatment for F4 patients and delay treatment for F1 patients who present to care.
引用
收藏
页码:1064 / 1071
页数:8
相关论文
共 50 条
  • [41] Cost-Effectiveness of the Third-Agent Class in Treatment-Naive Human Immunodeficiency Virus-Infected Patients in Portugal
    Aragao, Filipa
    Vera, Jose
    Pinto, Ines Vaz
    PLOS ONE, 2012, 7 (09):
  • [42] Long-term effectiveness and cost-effectiveness of screening for Hepatitis C virus infection
    Sroczynski, Gaby
    Esteban, Eva
    Conrads-Frank, Annette
    Schwarzer, Ruth
    Muehlberger, Nikolai
    Wright, Davene
    Zeuzem, Stefan
    Siebert, Uwe
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2009, 19 (03): : 245 - 253
  • [43] COST-EFFECTIVENESS OF BOCEPREVIR ADD-ON TREATMENT OF HEPATITIS C VIRUS GENOTYPE 1 PATIENTS IN DENMARK
    Ehlers, L.
    Ferrante, S.
    Kristensen, M. H.
    Leutscher, P. D. C.
    Chhatwal, J.
    VALUE IN HEALTH, 2013, 16 (07) : A354 - A354
  • [44] Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
    Phil McEwan
    Samantha Webster
    Thomas Ward
    Michael Brenner
    Anupama Kalsekar
    Yong Yuan
    Cost Effectiveness and Resource Allocation, 15
  • [45] Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease
    Leidner, Andrew J.
    Chesson, Harrell W.
    Xu, Fujie
    Ward, John W.
    Spradling, Philip R.
    Holmberg, Scott D.
    HEPATOLOGY, 2015, 61 (06) : 1860 - 1869
  • [46] Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations
    Martin, Natasha K.
    Vickerman, Peter
    Miners, Alec
    Foster, Graham R.
    Hutchinson, Sharon J.
    Goldberg, David J.
    Hickman, Matthew
    HEPATOLOGY, 2012, 55 (01) : 49 - 57
  • [47] Treatment of patients with chronic hepatitis C: Doubts about a cost-effectiveness study
    Bergmann, JF
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1997, 21 (04): : 336 - 337
  • [48] COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS IN RUSSIA
    Ignatyeva, V
    Pyadushkina, E.
    Derkach, E., V
    VALUE IN HEALTH, 2019, 22 : S646 - S647
  • [49] Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis
    T. Joseph Mattingly
    Julia F. Slejko
    Eberechukwu Onukwugha
    Eleanor M. Perfetto
    Shyamasundaran Kottilil
    C. Daniel Mullins
    PharmacoEconomics, 2020, 38 : 233 - 242
  • [50] THE COST-EFFECTIVENESS OF HEPATITIS C TREATMENTS IN TREATMENT NAIVE GENOTYPE 1 PATIENTS
    McGinnis, J. J.
    Hay, J. W.
    VALUE IN HEALTH, 2014, 17 (03) : A274 - A274